Stay updated on Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial

Sign up to get notified when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:27:52.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the response rates of Y90 radioembolization in combination with nivolumab for hepatocellular carcinoma (HCC) treatment in Asian patients.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:50.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for patients with hepatocellular carcinoma (HCC) who are planned for Y90 radioembolization. The new criteria include specific health conditions, prior treatments, and other medical requirements for participation in the study.
    Difference
    40%
    Check dated 2024-05-22T21:37:22.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:36:35.000Z thumbnail image

Stay in the know with updates to Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Y90-Radioembolization Plus Nivolumab in Asian HCC Clinical Trial page.